WAVE Life Sciences Ltd
WVE8.760USD
+0.130+1.51%
交易中 （美东）报价延迟15分钟
1.36B总市值
亏损市盈率 TTM
关于 WAVE Life Sciences Ltd 公司
Wave Life Sciences Ltd. 是一家生物技术公司。该公司致力于释放 RNA 药物（寡核苷酸）或靶向核糖核酸 (RNA) 的药物的潜力，以改变人类健康。其 RNA 药物平台 PRISMTM 结合了多种模式、化学创新和对人类遗传学的深刻见解，从而带来治疗罕见和流行疾病的科学突破。其 RNA 靶向模式工具包包括 RNA 编辑、剪接、反义沉默和 RNA 干扰 (RNAi)，使公司能够设计和持续交付最佳解决疾病生物学问题的候选药物。其多元化的产品线包括杜氏肌营养不良症、Alpha-1 抗胰蛋白酶缺乏症和亨廷顿氏病的临床项目，以及肥胖症的临床前项目。这些项目包括 WVE-N531、WVE-006 和 WVE-003。该公司还在构建新型 A-to-I RNA 编辑寡核苷酸 (AIMers) 产品线。
公司简介
公司代码WVE
公司名称WAVE Life Sciences Ltd
上市日期Nov 11, 2015
CEODr. Paul B. Bolno, M.D.
员工数量287
证券类型Ordinary Share
年结日Nov 11
公司地址7 Straits View
城市
上市交易所NASDAQ Global Market Consolidated
国家Singapore
邮编018936
电话6562363388
网址https://www.wavelifesciences.com/
公司代码WVE
上市日期Nov 11, 2015
CEODr. Paul B. Bolno, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
302.31K
--
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
25.00K
--
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
16.11K
--
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Chairman of the Board
Independent Chairman of the Board
16.11K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
16.11K
--
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
16.11K
--
Dr. Paul B. Bolno, M.D.
Dr. Paul B. Bolno, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher John Francis, Ph.D.
Dr. Christopher John Francis, Ph.D.
Senior Vice President - Corporate Development, Head - Emerging Areas
Senior Vice President - Corporate Development, Head - Emerging Areas
--
--
Dr. Gregory L. (Greg) Verdine, Ph.D.
Dr. Gregory L. (Greg) Verdine, Ph.D.
Director
Director
--
--
Dr. Peter Kolchinsky, Ph.D.
Dr. Peter Kolchinsky, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
302.31K
--
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
25.00K
--
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
16.11K
--
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Chairman of the Board
Independent Chairman of the Board
16.11K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
16.11K
--
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
16.11K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月15日 周四
更新时间: 5月15日 周四
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
11.44%
GSK plc
10.54%
Adage Capital Management, L.P.
7.87%
Maverick Capital, Ltd.
5.19%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
59.80%
持股股东
持股股东
占比
RA Capital Management, LP
11.44%
GSK plc
10.54%
Adage Capital Management, L.P.
7.87%
Maverick Capital, Ltd.
5.19%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
59.80%
股东类型
持股股东
占比
Investment Advisor
30.61%
Hedge Fund
23.74%
Investment Advisor/Hedge Fund
15.97%
Corporation
15.66%
Venture Capital
11.72%
Research Firm
1.66%
Individual Investor
0.59%
Pension Fund
0.31%
Bank and Trust
0.28%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
363
156.57M
98.38%
-1.61M
2025Q1
368
156.82M
101.38%
+1.16M
2024Q4
342
152.89M
100.27%
+6.14M
2024Q3
306
144.44M
97.59%
+25.71M
2024Q2
274
116.00M
94.13%
+429.46K
2024Q1
255
115.83M
95.69%
+2.66M
2023Q4
240
115.18M
98.42%
+19.70M
2023Q3
224
93.79M
97.86%
+5.83M
2023Q2
224
93.41M
97.80%
+7.66M
2023Q1
249
91.33M
96.13%
+7.12M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
18.20M
11.7%
--
--
Mar 31, 2025
GSK plc
16.78M
10.78%
--
--
Jun 06, 2025
Adage Capital Management, L.P.
12.52M
8.05%
+2.89M
+30.08%
Mar 31, 2025
Maverick Capital, Ltd.
8.26M
5.31%
+441.00
+0.01%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.21M
5.28%
+200.47K
+2.50%
Mar 31, 2025
Driehaus Capital Management, LLC
6.36M
4.09%
-353.85K
-5.27%
Mar 31, 2025
Shin Nippon Biomedical Laboratories Ltd
5.71M
3.67%
--
--
Jun 06, 2025
M28 Capital Management LP
5.66M
3.64%
--
--
Mar 31, 2025
Emerald Advisers LLC
5.06M
3.26%
-29.02K
-0.57%
Mar 31, 2025
Kynam Capital Management LP
4.90M
3.15%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
SPDR S&P Pharmaceuticals ETF
1.41%
Global X Genomics & Biotechnology ETF
1.02%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.81%
iShares U.S. Pharmaceuticals ETF
0.39%
First Trust Multi-Manager Small Cap Opportunities ETF
0.21%
Franklin Genomic Advancements ETF
0.17%
iShares Micro-Cap ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco Nasdaq Biotechnology ETF
0.11%
查看更多
SPDR S&P Pharmaceuticals ETF
占比1.41%
Global X Genomics & Biotechnology ETF
占比1.02%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.81%
iShares U.S. Pharmaceuticals ETF
占比0.39%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0.21%
Franklin Genomic Advancements ETF
占比0.17%
iShares Micro-Cap ETF
占比0.16%
ProShares Ultra Nasdaq Biotechnology
占比0.11%
Invesco Nasdaq Biotechnology ETF
占比0.11%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
